CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Inclusion Criteria:

1. ≥18 years old;

2. Sign on the informed consent;

3. Subjects must have histologically confirmed Large B-cell Lymphoma;

4. Subjects had been treated with anthracyclines and rituximab(or other CD20-targetedantibodies) and had relapsed, failed to respond, or progressed after at least twolines of therapy include autologous hematopoietic stem celltransplantation(auto-HSCT);

5. Subjects have accessible PET-positive lesion and have measurable CT-positive lesionaccording to Lugano Classification;

6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;

7. Adequate organ function;

8. Adequate vascular access for leukapheresis procedur;

9. Subjects who have previously received CD19 targeted therapy must confirm thatlymphoma lesions still expresss CD19;

10. Women of childbearing potential must agree to use highly effective methods ofcontraception for 1 year after the last dose of Relma-cel;

11. Males who have partners of childbearing potential must agree to use an effectivebarrier contraceptive method for 1 year after the last dose of Relma-cel.

Exclusion Criteria:

1. Central nervous system(CNS) only involvement by malignancy or primary CNS lymphoma;

2. History of another primary malignancyn that has not been in remission for at least 2years;

3. Subjects has HBV,HCV,HIV or syphilis nefection at the time of screening;

4. Active deep venous thrombosis(DVT)/Pulmonary embolism(PE),or active DVT/PE requiresanti-coagulation within 3 months prior to signing the ICF;

5. Subjects with uncontrolled systemic fungal,bacterial,viral or other infection;

6. Presence of acute or chronic graft-versus-host disease(GVHD);

7. History of any serious cardiovascular disease or presence of clinically relevant CNSpathology;

8. Pregnant or nursing woman;

9. Subjects using of any chemotherapy,corticisteriod,experiment agents,GVHDtherapies,radiation,allo-HSCT or any other therapies for lymphoma must go through aspecific wash-out period before leukapheresis;

10. Uncontrolled conditions or unwillingness or inability to follow the proceduresrequired in the protocol;

11. Received CAR T-cell or other genetically-modified T-cell therapy previously.